From the ∗Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS
†Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
‡Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
Conflicts of Interest and Source of Funding: G.C. reports personal fees for consulting, advisory role, and speakers' bureau from Roche/Genentech, Novartis, Pfizer, Lilly, Foundation Medicine, Samsung, and Daiichi Sankyo; honoraria from Ellipses Pharma; and fees for travel and accommodations from Roche/Genentech and Pfizer. M.R. reports fees for travel and accommodation from Sanofi. All the competing interests were outside the submitted work. For the remaining authors, none were declared.
Reprints: Giuseppe Curigliano, MD, PhD, Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy. E-mail: [email protected].
